Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects.
Brolucizumab
Diabetic macular edema (DME)
Intraocular inflammation (IOI)
Neovascular age-related macular degeneration (nAMD)
Retinal vascular occlusion
Retinal vasculitis
Side effects
Steroid-induced diabetes
Treatment
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
21
11
2022
accepted:
03
01
2023
pubmed:
13
1
2023
medline:
13
1
2023
entrez:
12
1
2023
Statut:
ppublish
Résumé
Anti-vascular endothelial growth factor (anti-VEGF) therapies have become the standard of care in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), resulting in a remarkable decrease in disease-related vision loss. However, the need for regular injections places a significant burden on patients, caregivers, and the healthcare system and improvements in vision may not be maintained long term. As a result of its drying potency and duration of action, brolucizumab, an intravitreal anti-VEGF therapy approved for the treatment of nAMD and DME, could decrease injection frequency for patients and provide an efficacious treatment; however, balancing its benefits and risks can be challenging. There have been reports of intraocular inflammation (IOI) in patients treated with brolucizumab, which, if left untreated, may result in severe vision loss. Recent evidence, however, indicates that early recognition of IOI and prompt and aggressive systemic corticosteroid treatment in response to posterior segment involvement can lead to favorable outcomes in these relatively rare but severe cases. A series of consensus meetings were conducted in 2022 between Swiss medical retina experts and diabetologists, discussing the current data for brolucizumab and exploring various challenges to its use, including the associated risk of IOI. The outcome is a collation of practical insights and guidance for ophthalmologists on the use of brolucizumab in patients with nAMD and DME, including patient selection and assessment, treatment regimen and monitoring, and the recognition and management of adverse events.
Identifiants
pubmed: 36633780
doi: 10.1007/s40123-023-00647-7
pii: 10.1007/s40123-023-00647-7
pmc: PMC10011261
doi:
Types de publication
Journal Article
Langues
eng
Pagination
639-655Informations de copyright
© 2023. The Author(s).
Références
GBD 2019 Blindness and Vision Impairment Collaborators. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144–60.
doi: 10.1016/S2214-109X(20)30489-7
World Health Organization. Blindness and vision impairment. 2022. https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment . Accessed 18 Nov 2022.
Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration–emerging pathogenetic and therapeutic concepts. Am Med. 2000;38(7):450–71.
Finger RP, Dennis N, Freitas R, et al. Comparative efficacy of brolucizumab in the treatment of neovascular age-related macular degeneration: a systematic literature review and network meta-analysis. Adv Ther. 2022;39(8):3425–48.
pubmed: 35678996
pmcid: 9309118
doi: 10.1007/s12325-022-02193-3
Starr MR, Xu D, Boucher N, et al. Characterizing progression to neovascular AMD in fellow eyes of patients treated with intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging Retina. 2021;52(3):123–8.
pubmed: 34038686
doi: 10.3928/23258160-20210302-02
Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–64.
pubmed: 22301125
pmcid: 3322721
doi: 10.2337/dc11-1909
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185–222.
pubmed: 28423385
doi: 10.1159/000458539
Teo ZL, Tham Y, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045, systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580–91.
pubmed: 33940045
doi: 10.1016/j.ophtha.2021.04.027
Kim LA, D’Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Clin Pathol. 2012;181(2):376–9.
doi: 10.1016/j.ajpath.2012.06.006
Wirkkala J, Kubin AM, Ohtonen P, Yisela J, Siik T, Hautala N. Visual outcomes of observation, macular laser and anti-VEGF in diabetic macular edema in type 1 diabetes: a real-world study. BMC Ophthalmol. 2022;22:258.
pubmed: 35681133
pmcid: 9178825
doi: 10.1186/s12886-022-02482-z
Zirpel J, Pfister IB, Gerhardt C, Garweg JG. Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland. Graefes Arch Clin Exp Ophthalmol. 2021;259:3569–78.
pubmed: 33942162
pmcid: 8589751
doi: 10.1007/s00417-021-05187-z
Peto T, Akerele T, Sagkriotis A, Zappacosta S, Clemens A, Chakravarthy U. Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: a real-world study. Diabet Med. 2022;39: e14746.
pubmed: 34796985
doi: 10.1111/dme.14746
Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2018. https://doi.org/10.1002/14651858.CD007419.pub6 .
doi: 10.1002/14651858.CD007419.pub6
pubmed: 30325017
pmcid: 6517139
Gale RP, Mahmood S, Devonport H. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye. 2019;33(Suppl 1):1–21.
pubmed: 30926932
pmcid: 6474281
doi: 10.1038/s41433-018-0300-3
Ebneter A, Michels S, Pruente C, et al. Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration. Sci Rep. 2020;10:20256.
pubmed: 33219242
pmcid: 7680100
doi: 10.1038/s41598-020-76354-1
Garweg JG, Gerhardt C. Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD)—a meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2021;259:2181–92.
pubmed: 33528645
pmcid: 8352813
doi: 10.1007/s00417-020-05048-1
Khanani AM, Skelly A, Bezlyak V, et al. SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States. Ophthalmol Retina. 2020;4(2):122–33.
pubmed: 31812631
doi: 10.1016/j.oret.2019.09.009
Giannakaki-Zimmermann H, Behrndt A, Hoffman L, et al. Predictors for 2-year functional and morphological outcomes of a treat-and-extend regimen with ranibizumab in patients with diabetic macular edema. Ophthalmic Res. 2021;64:465–75.
pubmed: 33498045
doi: 10.1159/000514721
Prenner JL, Halperin LS, Rycroft C, Hogue S, Liu ZW, Seibert R. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160(4):725–31.
pubmed: 26142721
doi: 10.1016/j.ajo.2015.06.023
Adams M, Holekamp N, Jackson T, et al. PCR61 Burden and impacts associated with caring for neovascular age-related macular degeneration and diabetic macular edema patients: a multinational caregiver survey. Value Health. 2022;25(7):S552.
doi: 10.1016/j.jval.2022.04.1406
Spooner KL, Mhlanga CT, Hong TH, Broadhead GK, Chang AA. The burden of neovascular age-related macular degeneration: a patient’s perspective. Clin Ophthalmol. 2018;12:2483–91.
pubmed: 30584267
pmcid: 6287411
doi: 10.2147/OPTH.S185052
NHS England and NHS Improvement. Transforming NHS Outpatient Care. 2020. https://www.locsu.co.uk/wp-content/uploads/2020/11/NHSEI-NOC-2020-25112020.pdf . Accessed 18 Nov 2022.
Kiss S, Chandwani HS, Cole AL, Patel VD, Lunacsek OE, Dugel PU. Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema. Clin Ophthalmol. 2016;10:2443–53.
pubmed: 27994438
pmcid: 5153291
doi: 10.2147/OPTH.S114006
Skelly A, Ferreira A, Bezlyak V, Jaffe D. PSS13 The economic and humanistic burden of patients on treatment for neovascular age-related macular degeneration. Value Health. 2017;20:A399–811.
doi: 10.1016/j.jval.2017.08.2391
Jansen ME, Krambeer CJ, Kermany DS, et al. Appointment compliance in patients with diabetic macular edema and exudative macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2018;49:186–90.
pubmed: 29554386
doi: 10.3928/23258160-20180221-06
Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220–6.
pubmed: 25193672
doi: 10.1136/bjophthalmol-2014-305327
Brynskov T, Munch IC, Larsen TM, Erngaard L, Sorensen TL. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. Acta Ophthalmol. 2020;98:132–8.
pubmed: 31282617
doi: 10.1111/aos.14183
Chandra S, Arpa C, Menon D, et al. Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration. Eye. 2020;34:1888–96.
pubmed: 31980748
pmcid: 7608465
doi: 10.1038/s41433-020-0764-9
Nguyen CL, Gillies MC, Nguyen V, et al. Characterization of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents. Ophthalmology. 2019;126:735–42.
pubmed: 30529685
doi: 10.1016/j.ophtha.2018.11.036
Rodríguez FJ, Wu L, Bordon AF, et al. Intravitreal aflibercept for the treatment of patients with diabetic macular edema in routine clinical practice in Latin America: the AQUILA study. Int J Retin Vitr. 2022. https://doi.org/10.1186/s40942-022-00425-w .
doi: 10.1186/s40942-022-00425-w
Angermann R, Hofer M, Huber AL, et al. The impact of compliance among patients with diabetic macular oedema treated with intravitreal aflibercept: a 48-month follow-up study. Acta Ophthalmol. 2022;100:e546–52.
pubmed: 34145756
doi: 10.1111/aos.14946
Swiss Public Assessment Report – Beovu. 2020. https://www.swissmedic.ch/dam/swissmedic/de/dokumente/zulassung/swisspar/67244-beovu-01-swisspar-20200306.pdf.download.pdf/SwissPAR%20%E2%80%93%20Beovu.pdf . Accessed 18 Nov 2022.
Swiss Public Assessment Report, extension of therapeutic indication – Beovu. https://www.swissmedic.ch/dam/swissmedic/fr/dokumente/zulassung/swisspar/67244-beovu-02-swisspar-20220803.pdf.download.pdf/SwissPAR_final.pdf . Accessed 18 Nov 2022.
Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128(1):89–99.
pubmed: 32574761
doi: 10.1016/j.ophtha.2020.06.028
Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84.
pubmed: 30986442
doi: 10.1016/j.ophtha.2019.04.017
Jhaveri C, Wykoff CC, Khanani AM, et al. Early residual fluid-free status and long-term BCVA outcomes: a treatment agnostic, post hoc analysis of pooled HAWK and HARRIER data. Am J Ophthalmol. 2022;236:12–9.
pubmed: 34695400
doi: 10.1016/j.ajo.2021.10.017
Singh RP, Jhaveri C, Wykoff C, et al. Efficacy outcomes of brolucizumab versus aflibercept in neovascular age-related macular degeneration patients with early residual fluid. Ophthalmol Retina. 2022;6(5):377–86.
pubmed: 34968756
doi: 10.1016/j.oret.2021.12.014
Schmidt-Erfurth U, Mulyukov Z, Gerendas BS, et al. Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis. Eye. 2022. https://doi.org/10.1038/s41433-022-02077-4 .
doi: 10.1038/s41433-022-02077-4
pubmed: 36577804
pmcid: 8873196
Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128:1050–9.
pubmed: 33207259
doi: 10.1016/j.ophtha.2020.11.011
Regillo C, Kertes P, Kaiser PK, et al. TALON, a phase IIIb study of brolucizumab versus aflibercept in a matched (treat-and-extend) regimen in patients with neovascular age-related macular degeneration: 32-week primary outcomes. Presented at American Society of Retina Specialists, New York, July 13–16, 2022.
Boltz A, Radunksy K, Weingessel B, Vécsei-Marlovits VP. Brolucizumab for pre-treated patients with choroidal neovascularization and signs of tachyphylaxis to aflibercept and bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2022;260(8):2561–6.
pubmed: 35348844
Bulirsch LM, Sassmannshausen S, Nadal J, Liegl R, Thiele S, Holz FG. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study. Br J Ophthalmol. 2022;106:1288–94.
pubmed: 33846161
doi: 10.1136/bjophthalmol-2020-318672
Giunta M, Meunier LG, Nixon D, Steeves J, Noble J. Early Canadian real-world experience with brolucizumab in anti-vascular endothelial growth factor-experienced patients with neovascular age-related macular degeneration: a retrospective chart review. Clin Ophthalmol. 2022;16:28852894.
doi: 10.2147/OPTH.S376199
Khanani AM, Zarbin MA, Barakat MR, et al. Safety outcomes of brolucizumab in neovascular age-related macular degeneration. JAMA Ophthalmol. 2022;140:20–8.
pubmed: 34817566
doi: 10.1001/jamaophthalmol.2021.4585
Khanani AM, Brown DM, Jaffe GJ, et al. MERLIN: phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid. Ophthalmology. 2022;129:974–85.
pubmed: 35537533
doi: 10.1016/j.ophtha.2022.04.028
Novartis. Novartis reports one year results of phase III MERLIN study evaluating Beovu
Swiss Medic Info. Beovu (Brolucizumab) product information. 2022. https://www.swissmedicinfo.ch/Default.aspx . Accessed 18 Nov 2022.
Schmouder RL, Maciejewski B, Karle A, et al. Immunologic features of Beovu
Bilgic A, Kodjikian L, March de Ribot F, et al. Real-world experience with brolucizumab in wet age-related macular degeneration: the REBA study. J Clin Med. 2021;10(13):2758.
pubmed: 34201729
pmcid: 8268719
doi: 10.3390/jcm10132758
Barchichat I, Thiel M, Job O, Schmid M. Bilateral blindness after uneventful brolucizumab injection for macular degeneration. BMC Ophthalmol. 2022;22:80.
pubmed: 35172763
pmcid: 8848976
doi: 10.1186/s12886-022-02305-1
Brown DM, Bandello AE, Bandello F, et al. KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema 2022. Am J Ophthalmol. 2022;238:157–72.
pubmed: 35038415
doi: 10.1016/j.ajo.2022.01.004
Wykoff CC, Garweg JG, Regillo C, et al. Brolucizumab for treatment of diabetic macular edema (DME): 100-week results from the KESTREL and KITE studies. Invest Ophthalmol Vis Sci. 2022;63(7):3849.
Chakraborty D, Sheth JU, Boral S, Sinha TK. Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: a real-world case series. Am J Ophthalmol Case Rep. 2021;24: 101197.
pubmed: 34504981
pmcid: 8414050
doi: 10.1016/j.ajoc.2021.101197
Pearce I, Amoaku W, Bailey C, et al. The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice. Eye. 2022;36:1725–34.
pubmed: 35314774
pmcid: 8936380
doi: 10.1038/s41433-022-02008-3
Holz FG, Iida T, Maruko I, Sadda SR. A consensus on risk mitigation for brolucizumab in neovascular age-related macular degeneration - patient selection, evaluation, and treatment. Retina. 2022;42:1629–37.
pubmed: 35994582
pmcid: 9387760
doi: 10.1097/IAE.0000000000003556
Fonollosa A, Gallego-Pinazo R, Sararols L, Adan A, Lopez-Galvez M, Figueroa MS. Guidance on brolucizumab management recommendations. Arch Soc Esp Oftalmol. 2022. https://doi.org/10.1016/j.oftale.2022.05.006 .
doi: 10.1016/j.oftale.2022.05.006
pubmed: 35882576
Sharma A, Kumar N, Parachuri N, et al. Brolucizumab—early real-world experience: BREW study. Eye. 2021;5:1045–7.
doi: 10.1038/s41433-020-1111-x
Aziz AA, Khanani AM, London N, et al. Real world efficacy and safety of brolucizumab in neovascular AMD: The REBEL study. Invest Ophthalmol Vis Sci. 2021;62(8):451.
Haensli C, Pfister IB, Garweg JG. Switching to brolucizumab in neovascular age-related macular degeneration incompletely responsive to ranibizumab or aflibercept: real-life 6-month outcomes. J Clin Med. 2021;10:2666.
pubmed: 34204266
pmcid: 8235134
doi: 10.3390/jcm10122666
Khanani A, Sadda SR, Sarraf D, et al. Comparative assessment of the maximum thickness of pigment epithelial detachments and sub-RPE fluid in patients treated with brolucizumab versus aflibercept in the HAWK & HARRIER studies. Presented at EURETINA Virtual Meeting, September 2021.
Maruko I, Okada AA, Iida T, et al. Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol. 2021;259:2857–9.
pubmed: 33723637
pmcid: 8380561
doi: 10.1007/s00417-021-05136-w
Lanzetta P, Loewenstein A. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Arch Clin Exp Ophthalmol. 2017;255:1259–73.
doi: 10.1007/s00417-017-3647-4
National Institute for Health and Care Excellence (NICE). NICE guideline 82. Age-related macular degeneration. 2018. https://www.nice.org.uk/guidance/ng82 . Accessed 18 Nov 2022.
Holz FG, Heinz C, Wolf A, Hoerauf H, Pleyer U. Intraocular inflammation when using brolucizumab. Ophthalmologist. 2021;118(3):248–56.
doi: 10.1007/s00347-021-01321-8
Garweg JG, Hänsli C. Pitfalls in the interpretation of intraocular inflammation in response to intravitreal brolucizumab injection. Ocul Immunol Inflamm. 2021. https://doi.org/10.1080/09273948.2021.1976220 .
doi: 10.1080/09273948.2021.1976220
pubmed: 34637659
Tervaert CJW. Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis. Clin Exp Immunol. 2009;156(3):377–85.
pubmed: 19309350
pmcid: 2691964
doi: 10.1111/j.1365-2249.2009.03885.x
Scherler L, Haas NA, Tengler A, Pattathu J, Mandilaras G, Jakob A. Acute phase of Kawasaki disease: a review of national guideline recommendations. Eur J Ped. 2022;181:2563–73.
doi: 10.1007/s00431-022-04458-z
Li J, Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol. 2022;18:540–57.
pubmed: 35585199
pmcid: 9116713
doi: 10.1038/s41574-022-00683-6